The left atrial appendage is a key site of thrombus formation in atrial fibrillation (AF) and can be occluded or removed at the time of cardiac surgery. There is limited evidence regarding the effectiveness of surgical left atrial appendage occlusion (S-LAAO) for reducing the risk of thromboembolism.
A trial fibrillation (AF) is the most common sustained arrhythmia and has been projected to affect 3.3 million US adults by 2020.
1 AF is associated with an increased risk of thromboembolic stroke. 2 In the setting of nonrheumatic AF, approximately 90% of strokes originate from the left atrial appendage (LAA), 3 which exhibits poor contractile function during AF, permitting blood stasis and thrombus formation. Although oral anticoagulation 4,5 is effective at reducing the risk of thromboembolic stroke, as few as half of all eligible patients use anticoagulation, 6 frequently citing high perceived hemorrhage risk, cost, and patient preference. The low rates of anticoagulant use and the understanding that AF-related thrombus formation is most likely to occur in the LAA has led to increasing interest in occluding the LAA as a potential alternative to anticoagulation, particularly among those with difficulty tolerating anticoagulation. LAA occlusion can be performed surgically (S-LAAO) at the time of cardiac surgery, yet use of S-LAAO varies widely among physicians. Although in aggregate, data 7 from 2 randomized trials 8,9 demonstrated percutaneous LAAO was noninferior to warfarin, no similar data exist for S-LAAO. Furthermore, there have been reports of increased thromboembolism risk due to incomplete S-LAAO with persistent LAA to left atrium communication. 10 These limited data on the effectiveness of S-LAAO have led to its class IIb recommendation in US 11 and European 12 guidelines. As a result, information on the safety and effectiveness of S-LAAO is needed. The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) was used to perform an analysis of S-LAAO vs no S-LAAO in a contemporary, nationally representative cohort of Medicare beneficiaries with AF who underwent cardiac surgery. The main study objective was to evaluate whether S-LAAO was associated with a lower risk of readmission for thromboembolism in a broad population including patients who were discharged with and without anticoagulation.
Methods

Data Source and Study Population
The STS ACSD is a national US registry that collects detailed in-hospital data on all adults undergoing cardiac surgery at more than 1000 participating institutions (approximately 90% of cardiac surgical programs in the United States). 13 Through the use of a validated deterministic linkage with fee-for-service Medicare claims data and the Medicare Denominator File, 14 longitudinal data on morbidity and mortality can be determined for patients aged 65 years and older with fee-for-service Medicare insurance coverage. Documentation of concomitant S-LAAO began on January 14, 2011 (data collection form version 2.73). This project was approved by the STS Task Force on Longitudinal Follow-up and Linked Registries Committee and the Duke University institutional review board. The Duke University institutional review board waived the need for informed consent given the nature of this study.
This retrospective cohort study included older patients (age ≥65 years) with a history of AF or atrial flutter undergoing first-time cardiac surgery (coronary artery bypass grafting [CABG] , mitral valve surgery ± CABG, or aortic valve surgery ± CABG). We excluded patients with planned offpump operations, endocarditis, double valve procedures (both aortic and mitral operations), congenital heart disease or cardiac transplant, left ventricular assist device, cardiogenic shock, missing data on S-LAAO, inability to link to Medicare claims, missing anticoagulation data, those without information on the primary surgical procedure, and those with a duplicate Medicare record number. Paroxysmal AF was defined by the STS ACSD as AF that terminates within 7 days of initiation. All other AF subtypes were combined for the purpose of this analysis and labeled nonparoxysmal AF because the data collection form does not differentiate between persistent and permanent AF. The STS Registry collects data on the use of oral anticoagulation within 24 hours of surgery and oral anticoagulation prescription at discharge. Because oral anticoagulation is typically discontinued more than 24 hours prior to surgery, the preoperative anticoagulation variable likely reflects patients who underwent an urgent procedure (and did not have anticoagulation held) or mistakenly received oral anticoagulation. The discharge anticoagulation variable reflects patients who were discharged with a prescription for oral anticoagulation, but it does not capture information regarding adherence or duration of therapy.
Geographic regions were defined based on the STS ACSD convention. 15 Baseline patient characteristics were defined by the STS ACSD data specifications. 16 Race and ethnicity were defined by patient (or family) report using fixed categories and were included in this analysis because race and ethnicity have been associated with perioperative risk and could be associated with use of S-LAAO. The glomerular filtration rate was calculated based on the Modification of Diet in Renal Disease equation.
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Treatment
The treatment of interest was S-LAAO (by any method) vs no S-LAAO, as defined by the STS Registry.
Key Points
Question Is surgical left atrial appendage occlusion associated with a reduction in long-term thromboembolic events?
Findings In this retrospective cohort study of 10 524 Medicare recipients with atrial fibrillation undergoing cardiac surgery, surgical left atrial appendage occlusion, compared with no surgical left atrial appendage occlusion, was significantly associated with lower risk of readmission for thromboembolism at 3 years (unadjusted, 4.2% vs 6.2%; adjusted hazard ratio, 0.67).
Meaning Surgical left atrial appendage occlusion may be of benefit in preventing thromboembolic events in older patients with atrial fibrillation undergoing cardiac surgery, although randomized trials would be necessary to provide definitive evidence.
Outcomes
The primary outcome was rehospitalization (ie, after the index hospitalization) for thromboembolism ( are outcomes that would not be expected to be affected by S-LAAO but could differ if treatment selection bias remained after adjustment. These prospectively designed falsification end points included pneumonia (ICD-9 codes 480.x, 481, 482.xx, 483.xx, 485, 486, 487.0, and 488.11) 20 and lower extremity fracture (ICD-9 codes 820.00-820.9, 821. 00-821.11, 821.20-821.39, 808.0-808.9, 823.02-823.92, 827.0-827.1, and 828.0-828.1 ).
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Statistical Analysis
Baseline characteristics of the study population by treatment group (S-LAAO vs no S-LAAO) were described using proportions for categorical variables and means with SDs for continuous variables. Differences between groups were tested using the χ 2 test for categorical variables and t test or
Wilcoxon test for continuous variables, depending on the nature of the distribution. We compared observed event rates by treatment group. For the all-cause mortality and composite end points, we used the Kaplan-Meier methods to calculate event rates. For thromboembolism, hemorrhagic stroke, and the falsification end points, we used the cumulative incidence function to calculate event rates. Unadjusted Cox proportional hazards models and Fine-Gray models were used to test between-group differences. The Markov Chain Monte Carlo method was used for imputation. Model results represent a pooled estimate generated by combing the results obtained by running each model in 10 independent imputed data sets.
To estimate the risk-adjusted association between S-LAAO vs no S-LAAO and outcomes, we used inverse probability-weighted (IPW) Fine-Gray or Cox proportional hazard models. Fine-Gray models were used for nonfatal study end points (thromboembolism, hemorrhagic stroke, pneumonia, and lower extremity fracture) to account for the competing risk of death, which is high in this population. Cox proportional hazards models were used for allcause mortality and the composite end point, which included death. We used nonparsimonious logistic regression models to predict the use of S-LAAO to generate a propensity score and, subsequently, an inverse propensity weight. Adjusted models were derived using IPW and did not additionally include individual variables that were used to generate the propensity score.
For the primary analysis, we used the following variables to derive the propensity score: age; sex; race/ethnicity; AF subtype; current smoking; body mass index; ejection fraction; congestive heart failure; prior stroke; hypertension; hyperlipidemia; diabetes; coronary artery disease; acute coronary syndrome prior to operation; glomerular filtration rate; lung disease; obstructive sleep apnea; congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke, transient ischemic attack, or thromboembolism (doubled), vascular disease, age 65 to 74 years, sex category (female) (CHA 2 DS 2 -VASc score); STS Risk Score; warfarin use within the 24 hours prior to surgery; academic hospital status; CABG volume; valve surgery volume; geographic region; operation type; mechanical valve; operation status; nonsternotomy surgical approach; number of diseased vessels; and presence of left main coronary artery disease. For secondary analyses, all variables (including surgical ablation) were included in the logistic regression model to derive a propensity score. The IPW cohorts were stabilized to prevent individuals with extreme weights from having excess influence. 22 The differences between observed characteristics in the weighted S-LAAO and no S-LAAO groups were examined by calculating the Cramer φ statistic. Small differences (<10%) suggest balance across the observed baseline covariates among patients in the S-LAAO and no S-LAAO groups. The primary analysis assessed the association between S-LAAO vs no S-LAAO and outcomes without adjustment for discharge anticoagulation strategy. We performed a series of prespecified secondary analyses to explore whether concomitant surgical ablation of AF or discharge anticoagulation strategies may affect the association between S-LAAO and risk of thromboembolism and all-cause mortality. We assessed the interaction between S-LAAO, discharge anticoagulation, and the study outcomes in the primary IPW models. Owing to the theoretical (but unproven) association between surgical AF ablation and stroke, we included concomitant surgical AF ablation in these secondary IPW models. Balance across the IPW populations for those discharged with and without oral anticoagulation was assessed by the Cramer φ statistics.
We performed a series of sensitivity analyses in which the primary and secondary analyses were repeated using fully adjusted regression models to ensure consistency of results. Cox proportional hazards models or Fine-Gray models were used, as appropriate. Hazard ratios (HRs) or subdistribution hazard ratios (sHRs) and their 95% CIs were reported. HRs and sHRs reflect results from Cox proportional hazards and Fine-Gray models, respectively. A P value less than .05 was considered statistically significant for all tests. All tests were 2-sided. Analyses were performed using SAS version 9.4 (SAS Institute Inc). The eAppendix in the Supplement contains additional information on the analytic approach.
After excluding patients with planned off-pump operations (n = 841), endocarditis (n = 205), double valve procedures (both aortic and mitral operations; n = 807), congenital heart disease or cardiac transplant (n = 92), left ventricular assist device (n = 42), cardiogenic shock (n = 123), missing data on S-LAAO (n = 64), inability to link to Medicare claims (n = 337), missing anticoagulation data (n = 429), those without information on the primary surgical procedure (n = 95), and those with a duplicate Medicare record number (n = 19), a total of 10 524 patients met the study criteria. The overall study cohort was older (median age, 76 years; interquartile range, 71-81 years), predominantly male (61%), and at high risk for stroke as demonstrated by a median CHA 2 DS 2 -VASc score of 4 (interquartile range, 3-5). Thirty percent of patients (n = 3163) underwent a mitral operation with or without CABG, 35% of patients (n = 3635) underwent an aortic procedure with or without CABG, and 35% of patients (n = 3726) underwent isolated CABG. Thirty-seven percent of patients (n = 3892) underwent S-LAAO. A comparison of the baseline characteristics of patients who did and did not receive S-LAAO at the time of cardiac surgery is presented in Table 1 . Compared with patients who did not undergo S-LAAO, those who received S-LAAO more commonly had nonparoxysmal AF, a higher ejection fraction, a lower STS Predicted Risk of Mortality score, and lower rates of common stroke risk factors (diabetes, hypertension, and prior stroke). S-LAAO was performed more commonly at the time of certain types of cardiac surgery (eg, mitral valve operations, surgical AF ablation), in certain geographic regions (eg, Great Lakes region), and in academic centers ( Table 2) .
Association Between S-LAAO and Outcomes
In the overall cohort, at a mean follow-up of 2.6 years, thromboembolism occurred in 5.4% of patients, hemorrhagic stroke in 0.9%, all-cause mortality in 21.5%, and the composite end point in 25.7% by 3 years. S-LAAO was associated with lower absolute rates of thromboembolism (4.2% (8) 605 (9) <.001
South Atlantic 872 (22) 1400 (21) Plains 313 (8) 639 (10) Pacific 442 (11) 693 (10) New England 189 (5) 462 (7) Mountain 218 (6) 352 (5) Mid-Atlantic 316 (8) 1032 (16) Great Lakes 965 (25) 990 (15) East South Central 280 (7) 459 (7) Procedural Characteristics vs 6.2%), all-cause mortality (17.3% vs 23.9%), and the composite end point (20.5% vs 28.7%), but no difference in rates of hemorrhagic stroke (0.9% vs 0.9%).
In unadjusted analyses, use of S-LAAO was associated with a significantly lower risk of thromboembolism (sHR, 0.66; 95% CI, 0.56-0.79; P < .001), all-cause mortality (HR, 0.70; 95% CI, 0.64-0.77; P < .001), and the composite end point (HR, 0.69; 95% CI, 0.63-0.75; P < .001) (Table 3; Figure) .
The IPW cohort for the primary analysis was wellbalanced based on assessment of the Cramer φ (eTable 1 in the Supplement) and the falsification end points that were not associated with S-LAAO use in the IPW models: readmission for lower extremity fracture (HR, 0.95; 95% CI, 0.72-1.26; P =. 72) or pneumonia (HR, 1.10; 95% CI, 0.93-1.30; P = .29) (eTable 2 in the Supplement).
The results of the IPW-adjusted analyses were similar to the unadjusted analyses, and S-LAAO was associated with a significantly lower risk of thromboembolism (sHR, 0.67; 95% CI, 0.56-0.81; P < .001), all-cause mortality (HR, 0.88; 95% CI, 0.79-0.97; P = .001), and the composite end point (HR, 0.83; 95% CI, 0.76-0.91; P < .001) ( Table 3) . Results were unchanged in sensitivity analyses using regression analyses (eTable 3 in the Supplement). The adjusted rates of the study end points by exposure group are depicted in eTable 4 in the Supplement.
To assess the extent to which the observed association between S-LAAO and outcomes could be mediated by S-LAAO being a marker for higher overall quality of care, the proportion of eligible patients receiving standard of care treatments were compared among hospitals that performed S-LAAO 50% or more of the time vs less than 50% of the time. When comparing hospitals that performed more vs less S-LAAO, there were no differences in the rates of discharge oral anticoagulation use, prescription of β-blocker or lipid-lowering medications among patients undergoing CABG, or use of an internal mammary artery among patients with CABG and left main or proximal left anterior descending artery disease (eTable 5 in the Supplement). Subsequent multivariate adjusted Fine-Gray models demonstrated that the association between S-LAAO and thromboembolism did not vary based on concomitant surgical ablation (P for interaction = .89) or AF subtype (paroxysmal vs nonparoxysmal; P for interaction = .64).
Association Between S-LAAO and Outcomes With Stratification by Discharge Anticoagulation Strategy
Anticoagulation was prescribed to 68.9% of patients (n = 2680) who received S-LAAO and 60.3% (n = 3996) who did not receive S-LAAO (P < .001). There was a significant interaction between S-LAAO, discharge anticoagulation, and all-cause mortality (P = .004). In the IPW cohort of patients discharged without anticoagulation (37%, n = 3848), S-LAAO was associated with a significantly lower rate of thromboembolism (sHR, 0.26; 95% CI, 0.17-0.40; P < .001), but not all-cause mortality, hemorrhagic stroke, or the composite end point (Table 3 ). In the IPW cohort of patients discharged with anticoagulation (63%, n = 6676), there was no association between S-LAAO, thromboembolism, and all- Rehospitalization for thromboembolism, hemorrhagic stroke, or all-cause mortality.
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Surgical Left Atrial Appendage Occlusion and Atrial Fibrillation-Associated Thromboembolism cause mortality, although S-LAAO was associated with a lower risk for hemorrhagic stroke (sHR, 0.32; 95% CI, 0.17-0.57; P < .001) ( Table 3) . Results were unchanged in sensitivity analyses using regression analyses (eTable 3 in the Supplement). The Cramer φ statistics assessing balance among the cohorts stratified by discharge anticoagulation status are displayed in eTable 6 in the Supplement. Among patients who received S-LAAO, there was no adjusted association between discharge anticoagulation and thromboembolism (P = .79).
Discussion
In a nationally representative cohort of older patients with AF undergoing cardiac surgery, S-LAAO (compared with no S-LAAO) was associated with a significantly lower risk of readmission for thromboembolism and all-cause mortality over the subsequent 3 years. Furthermore, the observed association between S-LAAO and lower rates of thromboembolism may have been primarily related to lower observed rates of thromboembolism in the substantial group of patients discharged without anticoagulation. While observational in nature, this analysis supports the use of S-LAAO in patients with AF at the time of cardiac surgery. Prior reports on surgical S-LAAO, including a recent meta-analysis (which included 171 patients from 3 randomized clinical trials and 3482 patients from 4 observational studies) 23 have generally supported the notion that S-LAAO is associated with a reduction in stroke and mortality. However, the individual reports did not account for concomitant surgical ablation and anticoagulation strategies, both of which could have a meaningful effect on AF-related morbidity and mortality. Furthermore, the individual observational studies included in the meta-analysis were generally small, single center, and included only 30-day follow-up; notably, the largest study 24 (N = 1777) included in the meta-analysis did not use any statistical adjustment. There were notable differences in the individual components of the composite end point, and LAAO was associated with a reduction in hemorrhagic stroke and cardiovascular death but increased rates of ischemic stroke.
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The current study has a number of key differences compared with the randomized WATCHMAN trials. In the current study, S-LAAO and no S-LAAO were compared in the overall population and in subpopulations defined by discharge anticoagulation strategies. In contrast, the randomized WATCHMAN trials 8,9 compared LAAO vs warfarin; in these studies, patients randomized to LAAO used short-term warfarin, which was discontinued after device endothelialization if the appendage was deemed sufficiently closed after assessment with transesophageal echocardiography. In the WATCHMAN meta-analysis, 7 the association between LAAO and a reduction in cardiovascular mortality appeared to be driven by a reduction in hemorrhagic stroke and occurred despite increased rates of ischemic stroke; therefore, the benefit appeared to be due to avoidance of anticoagulationrelated morbidity and mortality rather than a reduction in thromboembolism. The current study demonstrated that S-LAAO was associated with a significantly lower rate of thromboembolism among patients without oral anticoagulation. In the cohort of patients discharged with oral anticoagulation, S-LAAO was not associated with thromboembolism but was associated with a lower risk for hemorrhagic stroke, presumably related to eventual discontinuation of oral anticoagulation among S-LAAO patients.
The results from the current study have implications for the ongoing Left Atrial Appendage Occlusion Study (LAAOS) III (NCT01561651), 27 which is randomizing 4700 cardiac surgery patients with AF to S-LAAO vs no S-LAAO with 4 years of planned follow-up and a primary end point of stroke or systemic embolism. In this study, patients and the research team (except for the surgeon) are blinded to treatment assignment, and oral anticoagulation is recommended in both groups. Based on the results from the current study, the outcome of LAAOS III may depend on the proportion of patients who are discharged without anticoagulation or have anticoagulation discontinued after S-LAAO. The anticipated increased use of direct oral anticoagulants in LAAOS III compared with the current study will be an important difference between the 2 studies. Additional randomized studies comparing S-LAAO without anticoagulation vs systemic anticoagulation alone will be needed to define the optimal use of S-LAAO. Differences in unobserved covariates are of concern in nonrandomized observational analyses, particularly among older cohorts. To assess the likelihood for residual confounding in the IPW cohort, the associations between treatment (S-LAAO vs no S-LAAO) and 2 common admission diagnoses (pneumonia and lower extremity fracture) were tested. These admission diagnoses were selected because they are expected to be more common among frail individuals and those with increasing comorbidity burden. Although residual confounding can never be completely excluded in nonrandomized studies, the observed null association between treatment and the falsification end points supports that differences in unobserved covariates are likely minimal.
Limitations
There are important limitations associated with this study. First, treatment (S-LAAO vs no S-LAAO) was not randomized and the rationale for varying treatment decisions is unknown; although robust statistical methods were used to account for differences between groups, the potential for residual confounding cannot be ruled out. Second, the study population included adults 65 years of age and older with fee-for-service Medicare; therefore, the results may not be generalizable to younger individuals or those with different insurance. Third, study outcomes were defined using claims data rather than adjudicated end points as is the standard in randomized trials. Fourth, the STS Registry Data Collection Form version 2.73 does not collect data on the method of S-LAAO, and it is possible that the method of S-LAAO may be associated with the procedure's effectiveness. Similarly, the STS Registry does not contain information on the completeness of S-LAAO (presence or absence of a residual leak), which may also influence outcomes. Fifth, owing to differences in procedure characteristics, the results from this study may not be generalizable to patients who undergo LAAO via a percutaneous approach. Sixth, the determination of discharge anticoagulation was based on a variable that reflects patients who were discharged with a prescription for oral anticoagulation, but it does not capture information regarding adherence or duration of therapy. Therefore, the discharge anticoagulation variable may not reflect long-term anticoagulation; results of the exploratory analyses (with stratification by discharge anticoagulation) should be interpreted accordingly. Seventh, most patients discharged with anticoagulation were discharged with warfarin, so the results may not be generalizable to patients treated with direct oral anticoagulants.
Conclusions
Among older patients with AF undergoing concomitant cardiac surgery, S-LAAO compared with no S-LAAO was associated with a lower risk of readmission for thromboembolism over 3 years. These findings support the use of S-LAAO, but randomized trials are necessary to provide definitive evidence. Role of the Funder/Sponsor: The study sponsors had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
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eAppendix. Statistical Supplement
Descriptive Statistics
Baseline characteristics of the study population by treatment group (S-LAAO versus no S-LAAO) were described using proportions for categorical variables and means with standard deviations for continuous variables. These tables were generated using available data with imputation. Differences between groups were tested using the Chisquare test for categorical variables. Continuous variables with a non-normal distribution were analyzed using the Wilcoxon test. Normally distributed continuous variables were analyzed using a two sample t-test and equality of variance was considered. The comparison of baseline characteristics by treatment group (S-LAAO versus no S-LAAO) are depicted in Tables 1 and 2 . A similar approach was taken when creating the Supplemental Table 4 , proportion of eligible patients receiving standard of care treatments by hospitals with ≥50% vs. <50% S-LAAO use.
Unadjusted Event Rates
The Kaplan Meier method was used to calculate the unadjusted event rates for the endpoints of all-cause mortality and the composite endpoint (thromboembolism, hemorrhagic stroke, and death). The cumulative incidence function was used to calculate the unadjusted event rate for the endpoints of thromboembolism, hemorrhagic stroke, and the falsification endpoints (lower extremity fracture and pneumonia) in order to account for the competing risk of death which is high in this population. The unadjusted rates (calculated as per above) were plotted as a cumulative hazard function in Figure 1 .
Differences in unadjusted outcomes by treatment (S-LAAO versus no S-LAAO) were assessed using Cox Proportional Hazards models for the all-cause mortality and composite endpoints. Differences in unadjusted outcomes by treatment (S-LAAO versus no S-LAAO) were assessed using Fine-Gray models for the outcomes of thromboembolism, hemorrhagic stroke, and the falsification endpoints (lower extremity fracture and pneumonia); Fine-gray models were selected to account for the competing risk of death which is high In this population.
The approach described in this section was used consistently for all unadjusted analyses.
Risk-adjusted Associations for the Primary Analyses
To assess the risk adjusted association between treatment (S-LAAO vs. no S-LAAO) and outcomes, inverse probability weighted (IPW) adjustment was used for the primary analysis of the overall population (n=10,524). A non-parsimonious logistic regression analysis was performed to derive a propensity score for each patient, predicting likelihood of undergoing S-LAAO at the time of cardiac surgery. The following variables were used to generate a propensity score for the primary analysis: age, sex, race, AF subtype, current smoking, BMI, EF, CHF, prior stroke, hypertension, hyperlipidemia, diabetes, coronary artery disease, acute coronary syndrome prior to operation, glomerular filtration rate, lung disease, obstructive sleep apnea, CHA 2 DS 2 -VASc Score, STS Risk Score, warfarin use within the 24 hours prior to surgery, academic hospital status, CABG volume, valve surgery volume, geographic region, operation type, mechanical valve, operation status, non-sternotomy surgical approach, number of diseased vessels, and presence of left main coronary artery disease. These variables represented a comprehensive list of variables that are likely to be associated with treatment decisions and outcomes, including the decision to use or non-use S-LAAO. The adjusted population was weighted based on the inverse of the propensity score. In order to minimize the potential for extreme propensity score values from unduly influencing or biasing the study result, the propensity distributions for each subpopulation (S-LAAO and no S-LAAO populations) were stabilized.
Cramer Phi statistics or standardized differences as appropriate were used to assess for differences in observed characteristics in the S-LAAO and no S-LAAO subpopulations after inverse probability weighting. The Cramer Phi test was used to due to the number of multilevel categorical variables. Small differences in the Cramer Phi statistic or the standardized difference (<10%) suggest balance across the measured baseline covariates among patients in the S-LAAO and no S-LAAO groups. Imbalance in unmeasured characteristics in observational research has the potential to lead to substantially bias results. To assess for the possibility of residual confounding, falsification endpoints that were hypothesized to be associated with frailty were utilized: lower extremity fracture and pneumonia. A null association between S-LAAO and these endpoints, which should not be affected by S-LAAO, would suggest that residual confounding is less likely to influence the study results. Falsification testing was performed using unadjusted and IPW adjusted Fine-Gray models (Supplemental Table 2 ) to account for the competing risk of death. The variable for likelihood of receipt (vs. non-receipt) of S-LAAO (i.e. propensity score) was the only variable entered into the model for the adjusted analyses. Specifically, the variables used to generate the aforementioned propensity score were not added to the model.
The risk adjusted association between S-LAAO (vs. no S-LAAO) and the study outcomes were tested using Fine Gray models (for thromboembolism and hemorrhagic stroke) and Cox Proportional Hazards models (all-cause mortality, composite endpoint) as appropriate. The variable for likelihood of receipt (vs. non-receipt) of S-LAAO (i.e. propensity score) was the only variable entered into the model for the adjusted analyses. Specifically, the variables used to generate the aforementioned propensity score were not added to the model. The Markov Chain Monte Carlo method was utilized for imputation. Model results represent a pooled estimate generated by combing the results obtained by running each model in 10 independent imputed datasets.
Pre-specified Secondary Analyses
The association between S-LAAO and outcomes was assessed in a series of pre-specified secondary analyses after stratification based on whether a patient was discharged with a prescription for oral anticoagulation. The unadjusted incidence rates and statistical comparisons were calculated as described in the section "Unadjusted Event Rates."
The risk adjusted associations between S-LAAO and outcomes in the subpopulations defined by discharge anticoagulation status were determined using IPW. Within each subpopulation (defined by discharge anticoagulation strategy), a logistic regression analysis was performed to generate a propensity score depicting likelihood of receipt of S-LAAO. Similar to the primary analyses, a non-parsimonious approach was taken; all of the variables used to generate the propensity score for the primary analysis (listed above) plus surgical ablation were used to generate the propensity score for these secondary analyses. These propensity scores were used to generate two separate de novo IPW cohorts using the same methodology described in the section titled, "Risk Adjusted Associations for the Primary Analyses." The Cramer Phi and standardized differences statistics were used to assess for covariate balance in the two independent IPW populations.
As above, the risk adjusted association between S-LAAO (vs. no S-LAAO) and the study outcomes were tested using Fine Gray models (for thromboembolism and hemorrhagic stroke) and Cox Proportional Hazards models (allcause mortality, composite endpoint) as appropriate. The variable for likelihood of receipt (vs. non-receipt) of S-LAAO (i.e. propensity score) was the only variable entered into the model for the adjusted analyses. The imputation method was the same as for the primary analyses.
Sensitivity Analyses
In order to lessen the chance that the results of the primary and secondary analyses were spurious or unduly influenced by bias, these results were duplicated using classic multivariable regression and Fine-Gray or Cox Proportional Hazards models. As per above, Fine-Gray models were used for the endpoints that did not include death (thromboembolism and hemorrhagic stroke) and Cox Proportional Hazards models were used for all-cause mortality and the composite endpoint.
All analyses were fully adjusted by forcing variables into the model (i.e. selection was not used). When replicating the primary analyses, adjustment was performed using the following variables: age, sex, race, AF subtype, current smoking, BMI, EF, CHF, prior stroke, hypertension, hyperlipidemia, diabetes, coronary artery disease, acute coronary syndrome prior to operation, glomerular filtration rate, lung disease, obstructive sleep apnea, CHA 2 DS 2 -VASc Score, STS Risk Score, warfarin use within the 24 hours prior to surgery, academic hospital status, CABG volume, valve surgery volume, geographic region, operation type, mechanical valve, operation status, nonsternotomy surgical approach, number of diseased vessels, and presence of left main coronary artery disease. When replicating the secondary analyses (stratified by discharge anticoagulation status), all of these variables, plus surgical ablation, were used.
The interaction between S-LAAO, discharge anticoagulation status, and outcomes were tested in a fully adjusted Fine Gray model that included the preceding variables and an interaction term.
Exploratory Analyses
1. The association between discharge anticoagulation strategy and thromboembolism among patients who underwent S-LAAO was tested. Unadjusted and fully adjusted Fine-Gray models were used to detect differences in thromboembolism by discharge anticoagulation strategy. Abbreviations: AV, aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; EF, ejection fraction; GFR, glomerular filtration rate; MV, mitral valve; S-LAAO, surgical left atrial appendage occlusion; STS, Society of Thoracic Surgeons a The Cramer Phi statistic assesses for clinically significant differences between groups and may be more appropriate that standardized differences when there are multilevel categorical variables, which was frequently the case with this analysis. An absolute value of <0.10 suggests no clinically significant difference between groups. By this assessment, there were no clinically significant differences in adjustment variables between the S-LAAO and no S-LAAO groups in the primary IPW model. Abbreviations: AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age 75 years or older, Diabetes mellitus, Stroke, TIA, or TE, Vascular disease, Age 65 to 74 years, Sex Category; CHF, congestive heart failure; EF, ejection fraction; GFR, glomerular filtration rate; IPW, inverse probability-weighted a Dosed within 24 hours of surgery Supplemental Table 2 demonstrates the covariate balance (assessed by the Cramer Phi and standardized difference statistics) among the S-LAAO and no S-LAAO subgroups in the IPW models that are stratified by discharge anticoagulation strategy. The IPW population for those discharged with and without oral anticoagulation demonstrated balance among the S-LAAO and non S-LAAO groups, except for differences in age, region, and sternotomy rates among those discharged without anticoagulation.
